DURECT (NASDAQ:DRRX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a research note issued to investors on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Stock Performance

Shares of DURECT stock opened at $0.76 on Monday. The firm has a 50-day moving average of $0.82 and a 200-day moving average of $1.08. The stock has a market cap of $23.56 million, a PE ratio of -1.24 and a beta of 0.91. DURECT has a 52-week low of $0.70 and a 52-week high of $1.88.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC raised its stake in DURECT by 266.0% in the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 28,486 shares in the last quarter. Geode Capital Management LLC raised its stake in DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after purchasing an additional 14,658 shares in the last quarter. Finally, Richmond Brothers Inc. raised its stake in DURECT by 12.2% in the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after purchasing an additional 138,920 shares in the last quarter. Institutional investors and hedge funds own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.